Rizatriptan - Medication and Pregnancy KB

Rizatriptan

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Källén (control exposed to ergots), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used Rizatriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	157 / 527	Exposed groups of the whole study: drugs for migraine (ergots or triptans).
Källén (control unexposed, disease free), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used drugs for migraine (triptans or ergots) during pregnancy. Exposure to Rizatriptan provided and considered as a separate subgroup.	unexposed, disease free Infants born to women who did not use drugs for migraine.	157 / 1229901	Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327)
Nezvalová-Henriksen (Control unexposed, disease free), 2013	Norway 2004 - 2007	All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.	Rizatriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women did not redeem triptans during the study period (the population comparison group).	334 / 178565	Other triptans also studied.
Nezvalová-Henriksen (Control unexposed, sick), 2013	Norway 2004 - 2007	All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.	Rizatriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Triptan prescription redemption between 7 and 1 month prior to pregnancy only.	334 / 1095	Other triptans also studied.

Study

Country
Study period

Population source

Exposure definition

Non-exposure definition

Sample size

Rmk

Sweden
1995 - 2008

All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.

Infants born to women who had used Rizatriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).

exposed to other treatment, sick
Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).

157 / 527

Exposed groups of the whole study: drugs for migraine (ergots or triptans).

Sweden
1995 - 2008

All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.

Infants born to women who had used drugs for migraine (triptans or ergots) during pregnancy. Exposure to Rizatriptan provided and considered as a separate subgroup.

unexposed, disease free
Infants born to women who did not use drugs for migraine.

157 / 1229901

Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327)

Norway
2004 - 2007

All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.

Rizatriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study).

unexposed, disease free
Pregnant women did not redeem triptans during the study period (the population comparison group).

334 / 178565

Other triptans also studied.

Norway
2004 - 2007

All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.

unexposed, sick
Triptan prescription redemption between 7 and 1 month prior to pregnancy only.

334 / 1095

Other triptans also studied.

Case-control studies (cohort)

Study

Country
Study period

Case

Control

Sample size

Rmk

Warning! There are no case-control studies available for this drug.

1 study, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.